Synairgen completes a successful equity placing to fund the company’s trial for COVID-19 patients
Synairgen plc has raised US$17.6 million to fund the company’s trial for COVID-19 patients.
Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the company uses in vitro and ex vivo models to progress opportunities into clinical development. The biobank of human samples is used in these models to increase confidence in the likelihood of successful drug development.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Synairgen on its oversubscribed equity fundraising to fund the company’s trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients, manufacture of the drug and to strengthen the company’s balance sheet.
Talk to the deal team
Related deals
iwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets
iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.
Learn moreBezeq Online has been acquired by One Software Technologies
Bezeq Online has been acquired by ONE Software Technologies Ltd., enabling ONE Technologies to offer innovative solutions through full integration of advanced technology, real-time data analysis and proven service capabilities nationwide. ONE Technologies’ goal is to develop the next generation of service solutions, including AI-based tools, automation, multi-channel digital services and advanced CRM systems, all designed to deliver a continuous, accurate and effective customer experience.
Learn moreLargest AIM IPO in the business support services sector over the past five years has been completed
MHA plc raised US$131 million (£98 million) through a placing and retail offer, achieving a market capitalization of approximately US$363 million (£271 million) on admission. This was the largest AIM IPO in the business support services sector over the past five years. The IPO provides a platform for continued investment in technology, talent and acquisitions, supporting the group’s ambition to become a top 10 UK professional services firm.
Learn more